ABVC BIOPHARMA, INC.
ABVC BioPharma, Inc. (NASDAQ: ABVC) is an early-stage biotechnology company focused on developing innovative botanical drugs and medical devices to treat central nervous system and oncology/hematology diseases. The company maintains its website at www.abvc.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ABVC BIOPHARMA, INC. does
In the company’s own words
ABVC BioPharma, Inc. (NASDAQ: ABVC) is an early-stage biotechnology company focused on developing innovative botanical drugs and medical devices to treat central nervous system and oncology/hematology diseases. The company maintains its website at www.abvc.com.
The company operates through a portfolio of seven drug candidates and one medical device in various stages of clinical development. Its lead programs include ABV-1504 for major depressive disorder, which completed Phase II trials demonstrating significant efficacy, and ABV-1505 for adult attention-deficit hyperactivity disorder, currently in Phase II Part II development with interim analysis data submitted to the FDA. Additional CNS programs include ABV-1601 for depression in cancer patients. The oncology pipeline encompasses ABV-1702 for myelodysplastic syndrome, ABV-1703 for pancreatic cancer, and ABV-1501 for triple negative breast cancer combination therapy. The company also develops ABV-1701, a vitreous substitute for vitrectomy surgery, which completed Phase I trials in Australia with positive safety and efficacy results and is currently in Phase II development across multiple international sites.
ABVC operates through wholly-owned subsidiaries including BioLite Holding, Inc., which houses its drug development operations, and BioKey, Inc., a GMP-certified manufacturing facility capable of producing clinical trial materials from Phase I through Phase III and commercial manufacturing. The company generates revenue through outlicensing intellectual properties and providing contract development and manufacturing organization services. BioKey also manufactures and distributes a maitake mushroom dietary supplement line targeting immune health and cardiovascular benefits.
The company has established strategic partnerships with leading research institutions including Stanford University Medical Center, University of California San Francisco, Cedars-Sinai Medical Center, and multiple Taiwan medical centers for clinical trial execution. ABVC maintains collaborative agreements with related parties for co-development of additional oncology programs and clinical development services. The company's intellectual property portfolio includes granted patents covering polygala extracts for depression and ADHD treatment, as well as cross-linked oxidized hyaluronic acid for vitreous substitutes across multiple jurisdictions including the United States, Europe, Asia, and Australia.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1173313
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ABVC BIOPHARMA, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ABVC BIOPHARMA, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ABVC BIOPHARMA, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ABVC BIOPHARMA, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ABVC BIOPHARMA, INC.'s last four quarterly filings that the numbers alone won't show?”